Related Experiment Video
Updated: Jun 19, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Biological treatment in Felty's syndrome with profound neutropenia
Krzysztof Proc1, Marta Madej2, Piotr Wiland2
1Department of Rheumatology and Internal Medicine, Medical University Hospital, Wroclaw, Poland.
Abstract:
A triad of symptoms characterises Felty's syndrome: seropositive rheumatoid arthritis (RA), splenomegaly and neutropenia. The treatment of Felty's syndrome is based on using classic synthetic and biological disease-modifying anti-rheumatic drugs (DMARDs). In this article, we present a case of a patient with Felty's syndrome who was treated with biologic treatment. A systematic search of the literature on the electronic medical database was conducted. The drugs from the DMARD group, despite reducing the activity of the disease, may cause significant clinical complications. It is important to know about the diagnosis, differentiation and treatment of neutropenia and the prevention of febrile neutropenia. The article discusses the current therapeutic possibilities using both classical and biologic DMARDs.
Related Concept Videos
Long-term Depression
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Psychosis: Goals of Pharmacotherapy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Electroconvulsive Therapy

